228 related articles for article (PubMed ID: 35672205)
1. Rituximab in chronic immune mediated neuropathies: a systematic review.
Chaganti S; Hannaford A; Vucic S
Neuromuscul Disord; 2022 Aug; 32(8):621-627. PubMed ID: 35672205
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.
Latov N
Nat Rev Neurol; 2014 Aug; 10(8):435-46. PubMed ID: 24980070
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.
Briani C; Visentin A
Neurotherapeutics; 2022 Apr; 19(3):874-884. PubMed ID: 35349079
[TBL] [Abstract][Full Text] [Related]
4. Current treatments of chronic immune-mediated demyelinating polyneuropathies.
Brannagan TH
Muscle Nerve; 2009 May; 39(5):563-78. PubMed ID: 19301378
[TBL] [Abstract][Full Text] [Related]
5. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
Gorson KC; Natarajan N; Ropper AH; Weinstein R
Muscle Nerve; 2007 Jan; 35(1):66-9. PubMed ID: 16967492
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies.
Dalakas MC
J Peripher Nerv Syst; 2012 May; 17 Suppl 2():34-9. PubMed ID: 22548621
[TBL] [Abstract][Full Text] [Related]
7. Therapy of CIDP and related immune-mediated neuropathies.
Koski CL
Neurology; 2002 Dec; 59(12 Suppl 6):S22-7. PubMed ID: 12499467
[TBL] [Abstract][Full Text] [Related]
8. Update on therapy of chronic immune-mediated neuropathies.
Briani C; Cocito D; Campagnolo M; Doneddu PE; Nobile-Orazio E
Neurol Sci; 2022 Dec; 43(Suppl 2):605-614. PubMed ID: 33452933
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.
Lunn MP; Nobile-Orazio E
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD002827. PubMed ID: 27701752
[TBL] [Abstract][Full Text] [Related]
10. Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan.
Nobile-Orazio E; Gallia F; Terenghi F; Bianco M
Expert Rev Neurother; 2017 Aug; 17(8):755-765. PubMed ID: 28597710
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune polyneuropathies.
Naum R; Gwathmey KG
Handb Clin Neurol; 2023; 195():587-608. PubMed ID: 37562888
[TBL] [Abstract][Full Text] [Related]
12. Treatment of immune-mediated, dysimmune neuropathies.
Finsterer J
Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
[TBL] [Abstract][Full Text] [Related]
13. Nerve ultrasound characteristics of immunoglobulin M neuropathy associated with anti-myelin-associated glycoprotein antibodies.
Oka Y; Tsukita K; Tsuzaki K; Takamatsu N; Uchibori A; Chiba A; Hamano T
Muscle Nerve; 2022 Jun; 65(6):667-675. PubMed ID: 35353922
[TBL] [Abstract][Full Text] [Related]
14. A diagnostic score for anti-myelin-associated-glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti-myelin-associated-glycoprotein antibody.
Doneddu PE; Ruiz M; Bianchi E; Liberatore G; Manganelli F; Cocito D; Cosentino G; Benedetti L; Marfia GA; Filosto M; Briani C; Giannotta C; Nobile-Orazio E
Eur J Neurol; 2023 Feb; 30(2):501-510. PubMed ID: 35191144
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy.
Massa F; Zuppa A; Pesce G; Demichelis C; Bergamaschi M; Garnero M; Briani C; Ferrari S; Schenone A; Benedetti L
J Neurol Sci; 2020 Jun; 413():116777. PubMed ID: 32200107
[TBL] [Abstract][Full Text] [Related]
16. Ocrelizumab in a case of refractory chronic inflammatory demyelinating polyneuropathy with anti-rituximab antibodies.
Casertano S; Signoriello E; Rossi F; Di Pietro A; Tuccillo F; Bonavita S; Lus G
Eur J Neurol; 2020 Dec; 27(12):2673-2675. PubMed ID: 32875645
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.
Hu J; Sun C; Lu J; Zhao C; Lin J
J Neurol; 2022 Mar; 269(3):1250-1263. PubMed ID: 34120208
[TBL] [Abstract][Full Text] [Related]
18. [Cutting edge of diagnosis and treatment for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) based on the EAN/PNS guideline 2021].
Kuwabara S
Rinsho Shinkeigaku; 2024 May; 64(5):321-325. PubMed ID: 38644208
[TBL] [Abstract][Full Text] [Related]
19. Bochum ultrasound score allows distinction of chronic inflammatory from multifocal acquired demyelinating polyneuropathies.
Kerasnoudis A; Pitarokoili K; Gold R; Yoon MS
J Neurol Sci; 2015 Jan; 348(1-2):211-5. PubMed ID: 25534358
[TBL] [Abstract][Full Text] [Related]
20. Clinical spectrum of chronic acquired demyelinating polyneuropathies.
Saperstein DS; Katz JS; Amato AA; Barohn RJ
Muscle Nerve; 2001 Mar; 24(3):311-24. PubMed ID: 11353415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
